Trial Profile
Xolair Enhances Oral Desensitization in Peanut Allergic Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- 09 Sep 2015 New trial record